Maria Antonia Egea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Antonia Egea has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Maria Luisa García
Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, University of Barcelona, Barcelona, Spain
6 shared publications - Marta Espina
Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, University of Barcelona, Barcelona, Spain
3 shared publications A. Chauvet
Lab. Chimie Minérale et Générale, UFR Pharmacie, Montpellier, France
2 shared publicationsA. Salgueiro
Physicochemistry Department, Faculty of Pharmacy, University of Barcelona, Avda. Joan XXIII s/n. E-08028 Barcelona, Spain
2 shared publicationsF. Gamisans
Faculty of Pharmacy, Department of Physical Chemistry, Institute of Nanoscience and Nanotechnology (IN2UB), Barcelona University, Avda. Joan XXIII, s/n, 08028 Barcelona, Spain
2 shared publications- Amanda Cano
Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya. C/ Gran Via de Carles III, 85 bis, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III. C/ Melchor Fernández Almagro, 3, Fuencarral-El Pardo, 28029 Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 27 March 2018
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 16 (1) , 1-16
Memantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease: in vitro and in vivo characterization
Memantine, drug approved for moderate to severe Alzheimer’s disease, has not shown to be fully effective. In order to solve this issue, polylactic-co-glycolic (PLGA) nanoparticles could be a suitable solution to increase drug’s action on the target site as well as decrease adverse effects. For these reason, Memantine was loaded in biodegradable PLGA nanoparticles, produced by double emulsion method and surface-coated with polyethylene glycol. MEM–PEG–PLGA nanoparticles (NPs) were aimed to target the blood–brain barrier (BBB) upon oral administration for the treatment of Alzheimer’s disease. The production parameters were optimized by design of experiments. MEM–PEG–PLGA NPs showed a mean particle size below 200 nm (152.6 ± 0.5 nm), monomodal size distribution (polydispersity index, PI < 0.1) and negative surface charge (− 22.4 mV). Physicochemical characterization of NPs confirmed that the crystalline drug was dispersed inside the PLGA matrix. MEM–PEG–PLGA NPs were found to be non-cytotoxic on brain cell lines (bEnd.3 and astrocytes). Memantine followed a slower release profile from the NPs against the free drug solution, allowing to reduce drug administration frequency in vivo. Nanoparticles were able to cross BBB both in vitro and in vivo. Behavioral tests carried out on transgenic APPswe/PS1dE9 mice demonstrated to enhance the benefit of decreasing memory impairment when using MEM–PEG–PLGA NPs in comparison to the free drug solution. Histological studies confirmed that MEM–PEG–PLGA NPs reduced β-amyloid plaques and the associated inflammation characteristic of Alzheimer’s disease. Memantine NPs were suitable for Alzheimer’s disease and more effective than the free drug.
- 27 March 2018
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 16 (1) , 1-16
Open AccessMemantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease: in vitro and in vivo characterization
Memantine, drug approved for moderate to severe Alzheimer’s disease, has not shown to be fully effective. In order to solve this issue, polylactic-co-glycolic (PLGA) nanoparticles could be a suitable solution to increase drug’s action on the target site as well as decrease adverse effects. For these reason, Memantine was loaded in biodegradable PLGA nanoparticles, produced by double emulsion method and surface-coated with polyethylene glycol. MEM–PEG–PLGA nanoparticles (NPs) were aimed to target the blood–brain barrier (BBB) upon oral administration for the treatment of Alzheimer’s disease. The production parameters were optimized by design of experiments. MEM–PEG–PLGA NPs showed a mean particle size below 200 nm (152.6 ± 0.5 nm), monomodal size distribution (polydispersity index, PI < 0.1) and negative surface charge (− 22.4 mV). Physicochemical characterization of NPs confirmed that the crystalline drug was dispersed inside the PLGA matrix. MEM–PEG–PLGA NPs were found to be non-cytotoxic on brain cell lines (bEnd.3 and astrocytes). Memantine followed a slower release profile from the NPs against the free drug solution, allowing to reduce drug administration frequency in vivo. Nanoparticles were able to cross BBB both in vitro and in vivo. Behavioral tests carried out on transgenic APPswe/PS1dE9 mice demonstrated to enhance the benefit of decreasing memory impairment when using MEM–PEG–PLGA NPs in comparison to the free drug solution. Histological studies confirmed that MEM–PEG–PLGA NPs reduced β-amyloid plaques and the associated inflammation characteristic of Alzheimer’s disease. Memantine NPs were suitable for Alzheimer’s disease and more effective than the free drug.
- 1 December 2008
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 97 (12) , 5306-5317
PLGA nanospheres for the ocular delivery of flurbiprofen: Drug release and interactions
- 1 December 2008
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 97 (12) , 5306-5317
PLGA nanospheres for the ocular delivery of flurbiprofen: Drug release and interactions
- 1 January 2004
- Published by Taylor & Francis in Journal of Microencapsulation
- Vol. 21 (2) , 213-223
Stability and ocular tolerance of cyclophosphamide-loaded nanospheres
The physical and chemical stabilities of several formulations of cyclophosphamide-loaded polybutylcyanoacrylate (PBCA) nanospheres developed for an ophthalmic application as an immunosuppressive agent were studied over 6 months of storage at 4, 25 and 40°C in different experimental conditions. The physical stability of nanospheres was followed by the study of morphological (visual appearance) and morphometrical properties (mean particle size and polydispersity). The pH and tonicity of the suspensions and the association efficiency of the drug to polymeric system were also analysed to evaluate their chemical stability. The behaviour of colloidal suspensions with storage conditions was also followed by differential scanning calorimetry. The degradation of PBCA was affected by temperature and pH. The average particle size of all nanospheres remained practically unchanged throughout the study, with the polydispersity index being less than 0.1, corresponding to a monodisperse system. At 40°C, a loss of 25.9% of the initial association efficiency, especially in non-buffered pH 7.2 medium, was observed. The type of polymer degradation (surface erosion) was also determined by photon correlation spectroscopy. The results obtained from in vivo study of ocular tolerance indicate a good ocular tolerance for drug loaded to nanospheres.
- 1 January 2004
- Published by Taylor & Francis in Journal of Microencapsulation
- Vol. 21 (2) , 213-223
Stability and ocular tolerance of cyclophosphamide-loaded nanospheres
The physical and chemical stabilities of several formulations of cyclophosphamide-loaded polybutylcyanoacrylate (PBCA) nanospheres developed for an ophthalmic application as an immunosuppressive agent were studied over 6 months of storage at 4, 25 and 40°C in different experimental conditions. The physical stability of nanospheres was followed by the study of morphological (visual appearance) and morphometrical properties (mean particle size and polydispersity). The pH and tonicity of the suspensions and the association efficiency of the drug to polymeric system were also analysed to evaluate their chemical stability. The behaviour of colloidal suspensions with storage conditions was also followed by differential scanning calorimetry. The degradation of PBCA was affected by temperature and pH. The average particle size of all nanospheres remained practically unchanged throughout the study, with the polydispersity index being less than 0.1, corresponding to a monodisperse system. At 40°C, a loss of 25.9% of the initial association efficiency, especially in non-buffered pH 7.2 medium, was observed. The type of polymer degradation (surface erosion) was also determined by photon correlation spectroscopy. The results obtained from in vivo study of ocular tolerance indicate a good ocular tolerance for drug loaded to nanospheres.
- 1 January 2002
- Published by Taylor & Francis in Journal of Microencapsulation
- Vol. 19 (3) , 305-310
Cyclophosphamide-loaded nanospheres: analysis of the matrix structure by thermal and spectroscopic methods
This study reports on the preparation and evaluation of cyclophosphamide loaded-polyalkylcyanoacrylate nanospheres obtained by emulsion polymerization. Characterization by differential scanning calorimetry, infrared spectroscopy and X-ray diffraction can reveal state dispersion of the drug inside the nanospheres. Such information predicts the stability of the particles and the drug release behaviour. The study has indicated the prescence of a molecular dispersed system. The drug release behaviour was also studied.
- 1 January 2002
- Published by Taylor & Francis in Journal of Microencapsulation
- Vol. 19 (3) , 305-310
Cyclophosphamide-loaded nanospheres: analysis of the matrix structure by thermal and spectroscopic methods
This study reports on the preparation and evaluation of cyclophosphamide loaded-polyalkylcyanoacrylate nanospheres obtained by emulsion polymerization. Characterization by differential scanning calorimetry, infrared spectroscopy and X-ray diffraction can reveal state dispersion of the drug inside the nanospheres. Such information predicts the stability of the particles and the drug release behaviour. The study has indicated the prescence of a molecular dispersed system. The drug release behaviour was also studied.
- 29 August 2000
- Vol. 139 (3) , 114-9
Aceclofenac-loaded poly-epsilon-caprolactone nanocapsules. Effect of coadjuvants on morphometrical properties and drug entrapment.
The physicochemical properties of aceclofenac nanocapsules, prepared by interfacial precipitation of poly-e-caprolactone at the oil/water interface, have been studied. A Central Composite Design was used to investigate the influence of polymerization adjuvants on these properties on the elaboration of aceclofenac-loaded poly-e-caprolactone nanocapsules. In this way, the effect of polymer, oil and drug concentrations in organic phase on the size and encapsulation efficiency has been analyzed. The optimized nanocapsule formulation leads to use an initial concentration of drug (aceclofenac) of 0.8 mg/ml and 0.6% of oil (Miglyol 812), being the polymer and surfactant concentrations previously fixed.
- 29 August 2000
- Vol. 139 (3) , 114-9
Aceclofenac-loaded poly-epsilon-caprolactone nanocapsules. Effect of coadjuvants on morphometrical properties and drug entrapment.
The physicochemical properties of aceclofenac nanocapsules, prepared by interfacial precipitation of poly-e-caprolactone at the oil/water interface, have been studied. A Central Composite Design was used to investigate the influence of polymerization adjuvants on these properties on the elaboration of aceclofenac-loaded poly-e-caprolactone nanocapsules. In this way, the effect of polymer, oil and drug concentrations in organic phase on the size and encapsulation efficiency has been analyzed. The optimized nanocapsule formulation leads to use an initial concentration of drug (aceclofenac) of 0.8 mg/ml and 0.6% of oil (Miglyol 812), being the polymer and surfactant concentrations previously fixed.
- 1 January 1995
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 21 (15) , 1761-1771
Methotrexateloaded Nanoparticles: Analysis of Drug Content and Study of the Matrix Structure
Entrapment of methotrexate in biodegradable colloidal systems was studied. Nanospheres were characterized in terms of morphometrical properties, such as particle diameter and particle size distribution. The ability of two surfactants, and dextrans of different molecular weights to improve the entrapment of the drug in a polymeric matrix was also studied. The presence of sodium lauryl sulphate in the polymerization medium increased the drug content in the nanospheres, and this effect was more significant when Dextran T70 was added to the formulation. Thermal methods such as thermogravimetry, differential scanning calorimetry and thermomicroscopy were applied, in order to study the possible interactions between the polymer and the drug. Crystalline methotrexate domains were observed in the polybutylcyanoacrylate matrix by thermomicroscopy.
- 1 January 1995
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 21 (15) , 1761-1771
Methotrexateloaded Nanoparticles: Analysis of Drug Content and Study of the Matrix Structure
Entrapment of methotrexate in biodegradable colloidal systems was studied. Nanospheres were characterized in terms of morphometrical properties, such as particle diameter and particle size distribution. The ability of two surfactants, and dextrans of different molecular weights to improve the entrapment of the drug in a polymeric matrix was also studied. The presence of sodium lauryl sulphate in the polymerization medium increased the drug content in the nanospheres, and this effect was more significant when Dextran T70 was added to the formulation. Thermal methods such as thermogravimetry, differential scanning calorimetry and thermomicroscopy were applied, in order to study the possible interactions between the polymer and the drug. Crystalline methotrexate domains were observed in the polybutylcyanoacrylate matrix by thermomicroscopy.
- 1 March 1994
- Vol. 49 (3) , 211-7
Entrapment of cisplatin into biodegradable polyalkylcyanoacrylate nanoparticles.
The entrapment of cisplatin into biodegradable colloidal systems (polyalkylcyanoacrylates) was studied. Nanoparticles were characterized in terms of relevant parameters for organ distribution in vivo, such as particle diameter and particle size distribution, determined by correlation photon spectroscopy and transmission electron microscopy. Association efficiency was also evaluated by Plasma Emission Spectrophotometry. The ability of surfactants (sodium lauryl sulphate and poloxamer 188), and dextrans of various molecular weights, to improve the binding of the drug to polyalkylcyanoacrylates was also studied. The dextran content in nanoparticles, as determined by polarimetry, increases with the molecular weight of the polysaccharide. The highest value of association efficiency of cisplatin to nanoparticles was obtained in the presence of dextran 70 with sodium lauryl sulphate (0.08%) as stabiliser.
- 1 March 1994
- Vol. 49 (3) , 211-7
Entrapment of cisplatin into biodegradable polyalkylcyanoacrylate nanoparticles.
The entrapment of cisplatin into biodegradable colloidal systems (polyalkylcyanoacrylates) was studied. Nanoparticles were characterized in terms of relevant parameters for organ distribution in vivo, such as particle diameter and particle size distribution, determined by correlation photon spectroscopy and transmission electron microscopy. Association efficiency was also evaluated by Plasma Emission Spectrophotometry. The ability of surfactants (sodium lauryl sulphate and poloxamer 188), and dextrans of various molecular weights, to improve the binding of the drug to polyalkylcyanoacrylates was also studied. The dextran content in nanoparticles, as determined by polarimetry, increases with the molecular weight of the polysaccharide. The highest value of association efficiency of cisplatin to nanoparticles was obtained in the presence of dextran 70 with sodium lauryl sulphate (0.08%) as stabiliser.